A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure

Abstract. This single-center prospective clinical trial evaluated the combination of nivolumab plus bendamustine (NB) as a salvage regimen in classical Hodgkin lymphoma patients after failure of nivolumab monotherapy. A total of 30 patients received nivolumab (3 mg/kg) on D1,14 and bendamustine (90 ...

Full description

Bibliographic Details
Main Authors: Kirill V. Lepik, Natalia B. Mikhailova, Elena V. Kondakova, Yuri R. Zalyalov, Liudmila V. Fedorova, Luibov A. Tsvetkova, Polina V. Kotselyabina, Evgeniya S. Borzenkova, Elena V. Babenko, Marina O. Popova, Elena I. Darskaya, Vadim V. Baykov, Ivan S. Moiseev, Boris V. Afanasyev
Format: Article
Language:English
Published: Wolters Kluwer 2020-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000401

Internet

http://journals.lww.com/10.1097/HS9.0000000000000401

Similar Items